Advertisement
- United States
- /
- Pharma
- /
- NasdaqGM:PAHC
Phibro Animal Health Second Quarter 2025 Earnings: Misses Expectations
Phibro Animal Health (NASDAQ:PAHC) Second Quarter 2025 Results
Key Financial Results
- Revenue: US$309.3m (up 24% from 2Q 2024).
- Net income: US$3.19m (up 150% from 2Q 2024).
- Profit margin: 1.0% (up from 0.5% in 2Q 2024).
- EPS: US$0.079 (up from US$0.031 in 2Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Phibro Animal Health Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 2.3%. Earnings per share (EPS) also missed analyst estimates by 77%.
Looking ahead, revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are up 12% from a week ago.
Risk Analysis
You should always think about risks. Case in point, we've spotted 3 warning signs for Phibro Animal Health you should be aware of, and 2 of them don't sit too well with us.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGM:PAHC
Phibro Animal Health
Operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific.
Proven track record average dividend payer.
Similar Companies
Market Insights
Advertisement
Weekly Picks
TA
Talos on Tesla ·
The "Physical AI" Monopoly – A New Industrial Revolution
Fair Value:US$665.3637.3% undervalued
44 followersusers have followed this narrative
18 commentsusers have commented on this narrative
22 likesusers have liked this narrative
MA
Marek_Trnka on CSG ·
Czechoslovak Group - is it really so hot?
Fair Value:€5547.3% undervalued
42 followersusers have followed this narrative
1 commentusers have commented on this narrative
13 likesusers have liked this narrative
AL
alex30free on Swedencare ·
The Compound Effect: From Acquisition to Integration
Fair Value:SEK 46.2849.1% undervalued
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
1 likeusers have liked this narrative
Recently Updated Narratives
DA
DanielGC on UnitedHealth Group ·
UnitedHealth Group's Future Revenue Grows by 3.59%: What Will It Mean?
Fair Value:US$39525.8% undervalued
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
DO
Double_Bubbler on EnSilica ·
Why EnSilica is Worth Possibly 13x its Current Price
Fair Value:UK£590.2% undervalued
115 followersusers have followed this narrative
17 commentsusers have commented on this narrative
0 likesusers have liked this narrative
BE
Bejgal on MINISO Group Holding ·
MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x
Fair Value:US$27.0328.7% undervalued
52 followersusers have followed this narrative
3 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Popular Narratives
DA
davidlsander on Ubisoft Entertainment ·
Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share
Fair Value:€33.887.6% undervalued
59 followersusers have followed this narrative
5 commentsusers have commented on this narrative
25 likesusers have liked this narrative
AN
AnalystConsensusTarget on Microsoft ·
Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks
Fair Value:US$603.2233.5% undervalued
1277 followersusers have followed this narrative
2 commentsusers have commented on this narrative
9 likesusers have liked this narrative
AN
AnalystConsensusTarget on NVIDIA ·
NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026
Fair Value:US$253.0227.7% undervalued
1073 followersusers have followed this narrative
6 commentsusers have commented on this narrative
32 likesusers have liked this narrative
Trending Discussion
US
User on Tesla ·
When was the last time that Tesla delivered on its promises? Lets go through the list! The last successful would be the Tesla Model 3 which was 2019 with first deliveries 2017. Roadster not shipped. Tesla Cybertruck global roll out failed. They might have a bunch of prototypes (that are being controlled remotely) And you think they'll be able to ship something as complicated as a robot? It's a pure speculation buy.
5
|1
US
User on Tesla ·
This article completely disregards (ignores, forgets) how far China is in this field. If Tesla continues on this path, they will be fighting for their lives trying to sell $40000 dollar robots that can do less than a $10000 dollar one from China will do. Fair value of Tesla? It has always been a hype stock with a valuation completely unbased in reality. Your guess is as good as mine, but especially after the carbon credit scheme got canned, it is downwards of $150.
4
|0